What does this research mean for the field?

Lipid metabolism reprogramming, involving alterations in fatty acid synthesis, cholesterol metabolism, lipid droplet homeostasis, and mitochondrial β-oxidation, is a key mechanism driving endocrine therapy resistance in ER+ breast cancer. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To review the mechanisms by which lipid metabolism reprogramming drives endocrine therapy resistance in ER+ breast cancer and highlight potential combination therapy strategies.

September 14, 2026Frontiers in OncologyOpen Access

Lipid metabolism reprogramming: key mechanism of breast cancer endocrine therapy resistance

View Full Paper

Ask AI

Bookmark

To review the mechanisms by which lipid metabolism reprogramming drives endocrine therapy resistance in ER+ breast cancer and highlight potential combination therapy strategies.
Synthesized molecular evidence on lipid metabolic remodeling occurring in estrogen receptor-positive (ER+) breast cancer cells under endocrine therapy.
Evaluated functional adaptations across fatty acid synthesis, cholesterol metabolism, lipid droplet homeostasis, and mitochondrial fatty acid β-oxidation.
Metabolic shifts across fatty acid synthesis, cholesterol turnover, lipid droplet storage, and mitochondrial β-oxidation furnish drug-resistant tumor cells with survival advantages and steady energy production.
Altered lipid remodeling directly promotes drug-resistant phenotypes by rewiring downstream intracellular signaling cascades and epigenetic regulation pathways.
Developing therapeutic interventions that combine standard endocrine drugs with inhibitors targeting specific lipid metabolic pathways offers a viable route to reverse treatment resistance.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Review uncovers altered fatty acid and cholesterol metabolism driving endocrine therapy resistance in ER+ breast cancer, highlighting novel targets for combination therapies.

Cite This Study

Sui et al. (2026) studied this question.

synapsesocial.com/papers/6aa7b2b20926e14a848b13fe https://doi.org/10.3389/fonc.2026.1848165

View Full Paper

Ask AI

Bookmark

Implication

Review uncovers altered fatty acid and cholesterol metabolism driving endocrine therapy resistance in ER+ breast cancer, highlighting novel targets for combination therapies.

Lipid metabolism reprogramming: key mechanism of breast cancer endocrine therapy resistance

Key Points

Discussion

Implication

Cite This Study

Lipid metabolism reprogramming: key mechanism of breast cancer endocrine therapy resistance

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider